Citations

Showing 10 of 108152 citations.

Association Between Smoking and Molecular Subtypes of Colorectal Cancer
Wang, Xiaoliang , Amitay, Efrat L. , Harrison, Tabitha A. , Banbury, Barbara L. , Berndt, Sonja I. , Brenner, Hermann , Buchanan, Daniel D. , Campbell, Peter T. , Cao, Yin , Chang‐Claude, Jenny , Gallinger, Steven , Giannakis, Marios , Gunter, Marc J. , Nishihara, Reiko , Phipps, Amanda I. , Slattery, Martha L. , Song, Mingyang , Thibodeau, Steven, Guelpen, Bethany Van , Woods, Michael O. , Hoffmeister, Michael , Peters, Ulrike , Amitay, Efrat L , Chang-Claude, Jenny , Gunter, Marc J , Jenkins, Mark A , Moreno, Victor , Ogino, Shuji , Sakoda, Lori C , Schoen, Robert E , Song, Mingyang , Sun, Wei , Thibodeau, Steven N, Toland, Amanda Ewart , Woods, Michael O , Hoffmeister, Michael , Buchanan, Daniel D , Campbell, Peter T , Cao, Yin , Harrison, Tabitha A , Van Guelpen, Bethany , Brenner, Hermann , Wang, Xiaoliang , Chan, Andrew T. , Giles, Graham G. , Hopper, John L. , Jenkins, Mark A. , Lin, Yi , Moreno, Vı́ctor , Newcomb, Polly A. , Sakoda, Lori C. , Schoen, Robert E. , Sun, Wei , Hsu, Li

Mayo Clinic

JNCI Cancer Spectrum | June 13, 2021 | Volume: 5 | Issue: 4 | Pages: No page available

10.1093/jncics/pkab056 | PMID 34377935 Get It

Abstract Background Smoking is associated with colorectal cancer (CRC) risk. Previous studies suggested this association may be restricted to certain molecular subtypes of CRC, but large-scale comprehensive analysis is lacking. Methods A total of 9789 CRC cases and 11 231 controls of European ancestry from 11 observational studies were included. We harmonized smoking variables across studies and derived sex study–specific quartiles of pack-years of smoking for analysis. Four somatic colorectal tumor markers were assessed individually and in combination, including BRAF mutation, KRAS mutation, CpG island methylator phenotype (CIMP), and microsatellite instability (MSI) status. A multinomial logistic regression analysis was used to assess the association between smoking and risk of CRC subtypes by molecular characteristics, adjusting for age, sex, and study. All statistical tests were 2-sided and adjusted for Bonferroni correction. Results Heavier smoking was associated with higher risk of CRC overall and stratified by individual markers (Ptrend < .001). The associations differed statistically significantly between all molecular subtypes, which was the most statistically significant for CIMP and BRAF. Compared with never-smokers, smokers in the fourth quartile of pack-years had a 90% higher risk of CIMP-positive CRC (odds ratio = 1.90, 95% confidence interval = 1.60 to 2.26) but only 35% higher risk for CIMP-negative CRC (odds ratio = 1.35, 95% confidence interval = 1.22 to 1.49; Pdifference = 2.1 x 10-6). The association was also stronger in tumors that were CIMP positive, MSI high, or KRAS wild type when combined (Pdifference < .001). Conclusion Smoking was associated with differential risk of CRC subtypes defined by molecular characteristics. Heavier smokers had particularly higher risk of CRC subtypes that were CIMP positive and MSI high in combination, suggesting that smoking may be involved in the development of colorectal tumors via the serrated pathway.
A Sweet Voice: Acute Febrile Neutrophilic Dermatosis of the Larynx
Walker, Brian A. , Stull, Lindsey B., Hines, J. Peyton

Mayo Clinic

Ear, Nose & Throat Journal | June 13, 2021 | Volume: 102 | Issue: 10 | Pages: 629-631

10.1177/01455613211022098 | PMID 34121481 Get It

Significance Statement Acute febrile neutrophilic dermatosis (Sweet syndrome) is a rare idiopathic condition characterized by fever and whole-body rash of tender erythematous plaques of unknown etiology. Otorhinolaryngologic manifestations of the disease can be severe, yet they are sparsely reported in the literature. We present the first documented case of laryngeal involvement of Sweet syndrome.
Carnitine palmitoyltransferase-II deficiency: case presentation and review of the literature
McCormick, Benjamin J. , Chirilă, Răzvan M.

Mayo Clinic

Romanian Journal of Internal Medicine | June 12, 2021 | Volume: 59 | Issue: 4 | Pages: 420-424

10.2478/rjim-2021-0021 | PMID 34118800 Get It

Abstract Carnitine palmitoyltransferase-II deficiency, an autosomal recessive disorder, is the most common cause of recurrent rhabdomyolysis in adults. Recognition and avoidance of triggers, such as heavy exercise and stress, is key in prevention of further episodes; however, even with preventative measures, many patients will continue to experience periodic symptoms, including rhabdomyolysis. Avoidance of renal failure, correction of electrolyte disturbances and halting further muscle breakdown are the goals of treatment. It is essential for clinicians to recognize the signs and symptoms of acute disease in CPT-II deficiency. We present a case of recurrent rhabdomyolysis requiring hospitalization in a patient with CPT-II deficiency and review the literature for common clinical manifestations, diagnostics, and treatment strategies.
Cardiac surgeons' concerns, perceptions, and responses during the COVID‐19 pandemic
Luc, Jessica G.Y. , Ad, Niv , Nguyen, Tom C. , Collaborators, the COVID‐19 North American Cardiac Surgery Survey Working Group, Arora, Rakesh C. , Bender, Edward M. , Bethencourt, Daniel M., Bisleri, Gianluigi , Boyd, Douglas, Chu, Michael , Cruz, Kim I. de la , DeAnda, Abe , Farkas, Emily A. , Fedoruk, Lynn M., Fiocco, Michael, Forcillo, Jessica , Fradet, Guy, Gammie, James S. , Geirsson, Arnar , Gerdisch, Marc , Girard, Leonard N., Kaiser, Clayton A., Khabbaz, Kamal R. , Khoynezhad, Ali , Kiaii, Bob, Légaré, Jean‐François , Lehr, Eric J. , MacArthur, Roderick, McCarthy, Patrick M. , Mehall, John R., Merrill, Walter H. , Moon, Marc R. , Ouzounian, Maral , Peltz, Matthias , Perrault, Louis P. , Preventza, Ourania , Ramchandani, Mahesh, Ramlawi, Basel , Salenger, Rawn , Sekela, Michael , Stulak, John M., Sutter, Francis P., Timek, Tomasz A. , Whitman, Glenn, Williams, Judson B., Yanagawa, Bobby , Ye, Jian , Zeigler, Sanford , Bisleri, Gianluigi , Forcillo, Jessica , Fremes, Stephen E , Geirsson, Arnar , Gerdisch, Marc W , Girard, Leonard N , Legare, Jean-Francois , Moon, Marc R , Preventza, Ourania , Yanagawa, Bobby , Ye, Jian , Arora, Rakesh , Chu, Michael W A , Collaborators, the COVID‐19 North American Cardiac Surgery Survey Working Group, Balkhy, Husam H. , Boyd, Douglas, Engelman, Daniel T. , Fremes, Stephen E. , Kaneko, Tsuyoshi , Kent, William D. T. , Lee, Richard , Sellke, Frank W. , Wong, Daniel R.

Mayo Clinic

Journal of Cardiac Surgery | June 12, 2021 | Volume: 36 | Issue: 9 | Pages: 3040-3051

10.1111/jocs.15681 | PMID 34118080 Get It

Double PIK3CA Alterations and Parallel Evolution in Colorectal Cancers
Lin, Ming-Tseh, Zheng, Gang , Rodriguez, Erika F. , Parini, Vamsi, Xian, Rena R. , Zou, Ying , Gocke, Christopher D. , Eshleman, James R. , Xian, Rena , Zou, Ying S , Tseng, Li‐Hui

Mayo Clinic

American Journal of Clinical Pathology | June 12, 2021 | Volume: 157 | Issue: 2 | Pages: 244-251

10.1093/ajcp/aqab119 | PMID 34519764 Get It

Abstract Objectives To demonstrate clinicopathologic features and evaluate the clonality of double PIK3CA alterations in colorectal cancers (CRCs). Methods Clonality was examined in 13 CRCs with double PIK3CA alterations (1.7% of CRCs or 9.6% of PIK3CA-mutated CRCs). Multiregional analyses were performed to confirm subclonal PIK3CA alterations. Results PIK3CA alterations were detected within exon 9 (51%), exon 20 (23%), exon 1 (15%), and exon 7 (6.0%). CRCs with exon 7 alterations showed a significantly higher incidence of double PIK3CA alterations. Most double PIK3CA alterations consisted of a hotpsot alteration and an uncommon alteration; they were often clonal and present within a single tumor population. Multiregional analyses of CRCs with predicted subclonal double-alterations revealed multiclonal CRCs with divergent PIK3CA variant status originating from a common APC- and KRAS-mutated founder lineage of adenoma. Conclusions The findings supported multiclonal CRCs resulting from parallel evolution during the progression from adenoma to adenocarcinoma within the mitogen-activated protein kinase pathway, as previously demonstrated, or the mammalian target of rapamycin pathway. Further studies are warranted to elucidate clinical significance and potential targeted therapy for CRC patients with double PIK3CA alterations and impacts on clinical decision-making in patients with multiclonal CRCs harboring divergent PIK3CA mutational status.
Ophthalmoplegia and cranial nerve deficits in an adolescent with headache
Corredor, Margarita , Holmberg, Peter J., Corredor, Margarita M

Mayo Clinic

SAGE Open Medical Case Reports | June 12, 2021 | Volume: 9 | Issue: No issue available | Pages: No page available

10.1177/2050313x211024487 | PMID 34178348 Get It

Tolosa–Hunt syndrome is an idiopathic, inflammatory condition involving the cavernous sinus and is characterized by unilateral, painful ophthalmoparesis. The condition often begins with retro-orbital pain followed by select cranial nerve involvement. We report the case of a 17-year-old female whose presentation with progressive left-sided headache and ophthalmoparesis culminated in the diagnosis of Tolosa–Hunt syndrome. While many of her signs and symptoms have been previously reported in the rare pediatric cases of Tolosa–Hunt syndrome described in the literature, this case illustrates a unique presentation involving cranial nerves V and VII in addition to the more commonly reported cranial nerve III, IV, and VI palsies.
L-Arginine reduces downstream vascular contractility after flow-diverting device deployment: A preliminary study in a rabbit model
Ayers-Ringler, Jennifer , Parameswaran, Praveen Kolumam, Khashim, Zenith , Dai, Daying , Ding, Yonghong , Kallmes, David F. , Kadirvel, Ramanathan , Kolumam Parameswaran, Praveen, Ding, Yong-Hong , Dai, Daying

Mayo Clinic

Interventional Neuroradiology | June 12, 2021 | Volume: 28 | Issue: 2 | Pages: 183-189

10.1177/15910199211025107 | PMID 34120493 Get It

Background Flow diverters (FDs) are an effective treatment for intracranial aneurysms, though not free from hemorrhagic complications. A previous study demonstrated increased vascular contractility after FD-implantation as a potential mechanism of distal complications. Our study aimed to investigate whether L-arginine medication affects vascular contractility following FD deployment in a rabbit model. Methods FDs were implanted in the aorta of normal rabbits (+FD, n = 10), with sham-operated aorta as controls (n = 5). L-Arginine was given in the drinking water (2.25% L-arginine hydrochloride) of half of the +FD animals (+FD/+Arg). Force contraction vascular contractility studies were performed on the aortic rings proximal and distal to the FD using an organ bath. Total eNOS, eNOS(pS1177), eNOS(pT495), COX-2, and S100A4 were quantified by western analysis on total protein lysates from aortic segments, normalizing to GAPDH. Results Mean vascular contractility was 53% higher in distal relative to proximal aortic segments (P = 0.0038) in +FD animals, but were not significantly different in +FD/+Arg animals, or in sham-operated controls. The +FD animals expressed significantly reduced levels of eNOS(pS1177) than sham-operated controls (P = 0.0335), while both the +FD and +FD/+Arg groups had reduced levels of eNOS(pT495) relative to sham-operated controls (P = 0.0331 and P = 0.0311, respectively). Conclusion These results suggest that L-arginine medication reduces distal vascular contractility after FD treatment via nitric oxide production and thus might mitigate risk for downstream complications.
Sinonasal adenocarcinoma: Population‐based analysis of demographic and socioeconomic disparities
Low, Christopher M. , Balakrishnan, Karthik , Smith, Byron M., Stokken, Janalee K., O’Brien, Erin K. , O'Brien, Erin K , Balakrishnan, Karthik , Gompel, Jamie J. Van , Rowan, Nicholas R. , Choby, Garret

Mayo Clinic

Head & Neck | June 12, 2021 | Volume: 43 | Issue: 10 | Pages: 2946-2953

10.1002/hed.26783 | PMID 34117674 Get It

AbstractBackgroundSinonasal adenocarcinoma (SNAC) is a rare tumor. The impact of health disparities on survival, stage at presentation, and utilization of surgery is not well understood in patients with SNAC.MethodsThe Surveillance, Epidemiology, and End Results database was queried for cases of SNAC from 1973 to 2015. Cases were analyzed to assess for disparities in presentation, treatment, and survival.ResultsSNAC was identified in 630 patients. In a multivariate model of overall survival, an age increase of 10 years (Hazard Ratio (HR) = 1.37, p < 0.001), male sex (HR = 1.26, p = 0.045), and more recent decade of diagnosis (HR = 0.74, p < 0.001) were significantly related to time‐to‐death. There is a higher rate of SNAC‐related death in counties with more rural populations (p = 0.027).ConclusionFuture interventions targeting rural and less well‐educated populations may improve care with the goal of increasing the span of healthy life and reducing survival disparities related to SNAC.
Autograft Long Head Biceps Tendon Can Be Used as a Scaffold for Biologically Augmenting Rotator Cuff Repairs
Colbath, Gregory, Murray, Alison , Siatkowski, Sandra , Pate, Taylor, Krussig, Mario, Hawkins, Richard J. , Tokish, John M. , Mercuri, Jeremy , Tokish, John, Murray, Alison, Pill, Stephan G.

Mayo Clinic

Arthroscopy | June 12, 2021 | Volume: 38 | Issue: 1 | Pages: 38-48

10.1016/j.arthro.2021.05.064 | PMID 34126215 Get It

Purpose We create a viable, mechanically expanded autograft long head biceps tendon (LHBT) scaffold for biologically augmenting the repair of torn rotator cuffs. Methods The proximal aspect of the tenotomized LHBTs was harvested from patients during rotator cuff repair surgery and was mechanically formed into porous scaffolds using a surgical graft expander. LHBT scaffolds were evaluated for change in area, tensile properties, and tenocyte viability before and after expansion. The ability of endogenous tenocytes derived from the LHBT scaffold to promote tenogenic differentiation of human adipose‐derived mesenchymal stromal cells (ADMSCs) was also determined. Results Autograft LHBTs were successfully expanded using a modified surgical graft expander to create a porous scaffold containing viable resident tenoctyes from patients undergoing rotator cuff repair. LHBT scaffolds had significantly increased area (length: 24.91 mm [13.91, 35.90] × width: 22.69 mm [1.87, 34.50]; P = .011) compared with the native LHBT tendon (length: 27.16 mm [2.70, 33.62] × width: 6.68 mm [5.62, 7.74]). The structural properties of the autograft were altered, including the ultimate tensile strength (LHBT scaffold: .56 MPa [.06, 1.06] vs. native LHBT: 2.35 MPa [1.36, 3.33]; P = .002) and tensile modulus (LHBT scaffold: 4.72 MPa [−.80, 1.24] versus native LHBT: 37.17 MPa [24.56, 49.78]; P = .001). There was also a reduction in resident tenocyte percent viability (LHBT scaffold: 38.52% [17.94, 59.09] vs. native LHBT: 68.87% [63.67, 74.37]; P =.004). Tenocytes derived from the LHBT scaffold produced soluble signals that initiated ADMSC differentiation into an immature tenocyte‐like phenotype, as indicated by an 8.7× increase in scleraxis ( P = .040) and a 3.6× increase in collagen type III mRNA expression ( P = .050) compared with undifferentiated ADMSC controls. Conclusions The ability to produce a viable autologous scaffold from the proximal biceps tendon having dimensions, porosity, mechanical characteristics, native ECM components, and viable tenocytes that produce bioactive signals conducive to supporting the biologic augmentation of rotator cuff repair surgery has been demonstrated. Clinical Relevance This biologically active construct may help to improve the quality of healing and regeneration at the repair site of rotator cuff tears, especially those at high risk for retear.
Setting the Beta-Lactam Therapeutic Range for Critically Ill Patients: Is There a Floor or Even a Ceiling?
Frazee, Erin N. , Webb, Andrew , Pais, Gwendolyn, Jannetto, Paul J. , Rule, Andrew D. , Scheetz, Marc H.

Mayo Clinic

Critical Care Explorations | June 11, 2021 | Volume: 3 | Issue: 6 | Pages: e0446

10.1097/cce.0000000000000446 | PMID 34136822 Get It

OBJECTIVES: Beta-lactam antibiotics exhibit high interindividual variability in drug concentrations in patients with critical illness which led to an interest in the use of therapeutic drug monitoring to improve effectiveness and safety. To implement therapeutic drug monitoring, it is necessary to define the beta-lactam therapeutic range—in essence, what drug concentration would prompt a clinician to make dose adjustments up or down. This objective of this narrative review was to summarize evidence for the “floor” (for effectiveness) and “ceiling” (for toxicity) for the beta-lactam therapeutic range to be used with individualized therapeutic drug monitoring. DATA SOURCES: Research articles were sourced from PubMed using search term combinations of “pharmacokinetics,” “pharmacodynamics,” “toxicity,” “neurotoxicity,” “therapeutic drug monitoring,” “beta-lactam,” “cefepime,” “meropenem,” “piperacillin/tazobactam,” “ICU,” and “critical illness.” STUDY SELECTION: Articles were selected if they included preclinical, translational, or clinical data on pharmacokinetic and pharmacodynamic thresholds for effectiveness and safety for beta-lactams in critical illness. DATA SYNTHESIS: Experimental data indicate a beta-lactam concentration above the minimum inhibitory concentration of the organism for greater than or equal to 40–60% of the dosing interval is needed, but clinical data indicate that higher concentrations may be preferrable. In the first 48 hours of critical illness, a free beta-lactam concentration at or above the susceptibility breakpoint of the most likely pathogen for 100% of the dosing interval would be reasonable (typically based on Pseudomonas aeruginosa). After 48 hours, the lowest acceptable concentration could be tailored to 1–2× the observed minimum inhibitory concentration of the organism for 100% of the dosing interval (often a more susceptible organism). Neurotoxicity is the primary dose-dependent adverse effect of beta-lactams, but the evidence remains insufficient to link a specific drug concentration to greater risk. CONCLUSIONS: As studies advance the understanding of beta-lactam exposure and response in critically ill patients, it is essential to clearly define the acceptable therapeutic range to guide regimen selection and adjustment.